Piramal Pharma lifts Yapan Bio stake to 33.33% in ₹122 crore CDMO push
What's the deal? Piramal Pharma Limited (PPL)Dealroom has a profile for this one. Try Dealroom → invested INR 101.77 crore — about US$13.7 million — for a 27.78% equity stake in Hyderabad-based Yapan Bio Pvt Ltd, disclosed in a press release dated December 21, 2021. Yapan is a contract development and manufacturing organisation (CDMO) focused on biologics, bio-therapeutics, and vaccines. The stake was acquired through primary and secondary share purchases.
What's the endgame? PPL said the investment augments Piramal Pharma Solutions (PPS), its CDMO business, by broadening its offerings in large molecules. Specifically, the company linked the move to development and manufacturing support for human clinical trials.
Stake math. On April 4, 2022, PPL bought an additional 5.55% for Rs. 20.35 crore, lifting its aggregate stake to 33.33% as of March 31, 2023. For FY2023 consolidation, PPL accounted for Yapan's share of loss at Rs. 0.20 crore.
Why now? On October 18, 2022, Yapan opened a new process development facility at Genome Valley, Hyderabad, under a US$1 million expansion plan. It was the first major expansion since Piramal's December 2021 investment. The facility supports end-to-end development of RNA, DNA, and gene therapy products starting from plasmids.
The bigger picture. The Yapan position sits alongside other partnership structures at PPL, including a 49% stake in Allergan India Private LimitedDealroom has a profile for this one. Try Dealroom →, a joint venture with AllerganDealroom has a profile for this one. Try Dealroom → — now part of AbbVieDealroom has a profile for this one. Try Dealroom → — targeting the Indian formulations market. For scale, PPL's paid-up share capital stood at about INR 1,193.32 crore as of March 31, 2023.
The signal. PPL is building CDMO capabilities through minority stakes and joint ventures rather than full acquisitions. The common thread across its disclosures is platform expansion — and a clear tilt toward the growing biologics segment.
Read more: Multibagg
Image credit: ITB495
